Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States

by Hernandez, Luis, Shah, Anshul, Zhao, Qi, Milentijevic, Dejan, Kharat, Akshay
Published in Am Health Drug Benefits (2020)

Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

by Burudpakdee, Chakkarin, Shah, Anshul, Joish, Vijay N., Divers, Christine H., Yaldo, Avin
Published in Am Health Drug Benefits (2014)

Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion

by Bradshaw, Steven E., Gala, Smeet, Nanavaty, Merena, Shah, Anshul, Mwamburi, Mkaya, Kefalas, Panos
Published in BMC Ophthalmol (2016)

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

by Hernandez, Luis, Kuwabara, Hiroyo, Shah, Anshul, Yamabe, Kaoru, Burnett, Heather, Fahrbach, Kyle, Koufopoulou, Maria, Iwakiri, Ryuichi
Published in Pharmacoeconomics (2019)